Early Outcomes of Edwards INSPIRIS RESILIA Valve in Clinical Practice

Abstract

Objective: The Edwards INSPIRIS RESILIA valve is the first in a new class of biological valve prostheses with anticalcification properties, improved hemodynamics and prolonged longevity as compared to other available biological prothesis. The aim of our study was to evaluate the clinical outcomes and hemodynamic performance of this new valve. Methods: From September 2017 to September 2019, 84 patients underwent aortic valve replacement with an INSPIRIS RESILIA valve. Patients with acute aortic dissection were excluded. The pre-operative characteristics, postoperative outcomes and early hemodynamic performances of the valves implanted were analyzed. Results: The preoperative demographics, intraoperative data, postoperative outcomes and postoperative echographic findings per valve sizes prior to discharge, are summarised in Table 1, Table 2, Table 3 and Table 4, respectively. The average age at implantation was 58.4 years. The intraoperative mortality rate in this cohort was 1.19% (n=1). The in-hospital mortality was 2.38% (n=2). The rate of postoperative CVA was 3.57% (n=3) and 3 patients (3.57%) required a pacemaker post operatively. 1 patient had prosthetic valve endocarditis post-operatively (1.19%). The average maximum and mean gradients per valve size implanted were very satisfactory (Table 4). No patients had moderate or severe paravalvular leaks or aortic regurgitation on echocardiogram. Conclusions: Our results showed very satisfactory early clinical outcomes following implantation of INSPIRIS RESILIA valves. Early echographic data show excellent hemodynamic performance of the aortic valve prosthesis.